May 17th 2024
A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Novel Therapeutic Regimen Achieves Responses in Elderly Patients with AML/MDS
June 1st 2021Most elderly patients with acute myeloid leukemia and myelodysplastic syndromes cannot undergo intensive chemotherapy, but more than half of the patients in a new study responded to a regimen of ultra low–dose decitabine and low-dose cytarabine with G-CSF.
Bispecific CD3/CD123-Targeted Antibody APVO436 Shows Promise in AML/MDS
May 31st 2021Investigators successfully established the phase 2 dose of APVO436 for patients with acute myeloid leukemia or myelodysplastic syndrome after an acceptable safety profile was achieved in patients with responses to therapy.
Ublituximab Plus Umbralisib Considered for Treatment of CLL/SLL by FDA
May 26th 2021Based on phase 3 data supporting the use of ublituximab in combination with umbralisib versus an existing standard-of-care regimen for chronic lymphocytic leukemia and small cell lymphoma, the FDA has moved forward with a review of the application for approval.
IND for CD20-Targeted CAR T-cell Therapy Is Accepted by FDA for R/R CLL
May 11th 2021MB-106, a CD20-targeted CAR T-cell therapy that has shown promise in the treatment of B-cell non-Hodgkin lymphoma, is now being considered for patients with relapsed or refractory CD20-positive chronic lymphocytic leukemia.
Childhood Down Syndrome Remains Strong Risk Factor for Leukemia, Specifically Associations With AML
May 4th 2021A retrospective study evaluating over 3.9 million children found that Down syndrome was a strong risk factor for the development of childhood leukemia and has a stronger association with acute myeloid leukemia than previously recorded.
Low-Intensity Chemotherapy Without Intensified Pegaspargase Cured Most Patients With Low-Risk B-ALL
May 2nd 2021Data in the Journal of Clinical Oncology found that low-intensity chemotherapy without additional intensified pegaspargase cured almost all patients treated on the Children’s Oncology Group AALL0331 trial.
Phase 1/2 Trial Demonstrates Activity of Pirtobrutinib in CLL, B-Cell Malignancies
April 1st 2021Research investigating the highly selective, reversible BTK inhibitor pirtobrutinib found the drug was safe and active for treating patients with chronic lymphocytic leukemia as well as other B-cell malignancies.
Whole-Genome Sequencing May Improve Prognosis Accuracy for AML/MDS Versus Traditional Cytogenetics
April 1st 2021According to a single-institution study of patients with a known or suspected diagnosis of AML or MDS, whole-genome sequencing may provide better predictive ability of patients’ risk status than traditional methods.
FDA Approves Expanded Indication of Daunorubicin/Cytarabine to Include Children With AML
March 31st 2021The FDA approved a revised label for daunorubicin/cytarabine to treat newly-diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged 1 and older.
Combination Treatment With Eprenetapopt and Azacitidine Shows Promise for TP53-Mutant MDS and AML
March 2nd 2021“The [phase 1b/2] data [are] promising and support the current phase 3, multicenter trial, which we hope will lead to FDA approval and a new much-needed treatment option for this patient population,” said David Sallman, MD.
Using Mobile Apps May Be Feasible for Promoting Drug Adherence in ALL
February 26th 2021Study results from the Journal of Medical Internet Research indicated that medication adherence by way of reminders on mobile devices for patients with acute lymphoblastic leukemia and their caregivers may have validity.
Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia
February 24th 2021A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.